アキヤマ　シンジ   AKIYAMA Shinji   秋山　伸二    所属   松山大学  薬学部 医療薬学科    職種   教授
言語種別	英語
発行・発表の年月	2026/07
形態種別	学術論文
査読	査読あり
標題	Association between Coexisting Dementia and Mortality in Patients Receiving Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Nationwide Real-world Database Study
執筆形態	共著
掲載誌名	JMA Journal
掲載区分	国外
出版社・発行元	The Japanese Association of Medical Sciences
巻・号・頁	pp.1-9
総ページ数	9
担当区分	最終著者
著者・共著者	Masaki Sogame, Yasutaka Ihara, Shoichiro Yamamoto, Maya Shimasaki, Tomohisa Kurata, Shinji Akiyama
概要	This nationwide real-world database study investigated whether coexisting dementia is associated with mortality in patients with EGFR-mutated non-small cell lung cancer receiving first-line oral EGFR tyrosine kinase inhibitors (EGFR-TKIs). Using a Japanese administrative claims database, the authors identified 13,281 eligible patients treated between 2018 and 2024, of whom 282 (2.1%) had dementia. The primary outcome was 3-year all-cause mortality. Patients with dementia were older and showed poorer outcomes than those without dementia. The 3-year mortality rate was 41.9% in the dementia group versus 30.8% in the non-dementia group, and coexisting dementia was independently associated with higher mortality after adjustment (adjusted hazard ratio 1.35, 95% CI 1.06-1.73). In addition, medication adherence at 1 year was lower among patients with dementia. Among patients with dementia, preserved functional status was associated with lower mortality. These findings suggest that dementia is an important prognostic factor in patients receiving oral EGFR-TKIs and that maintaining functional status may help improve outcomes in this population.